search
Back to results

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Comparator: Sitagliptin phosphate
Comparator: Placebo
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 78 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 - 78 years of age
  • Currently on metformin monotherapy

Exclusion Criteria:

  • History of Type 1 diabetes mellitus or ketoacidosis
  • Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks
  • Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery
  • Currently participating in a study or has participated in a study with or without an investigational compound or device within the past 12 weeks
  • History of active liver disease such as chronic active hepatitis B or C, cirrhosis or symptomatic gallbladder disease
  • HIV positive
  • Pregnant, breast-feeding or planning to become pregnant during the study
  • User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Sitagliptin

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change From Baseline in Hemoglobin A1c (A1C) at Week 24
    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

    Secondary Outcome Measures

    Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day
    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
    Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day
    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
    Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.
    Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

    Full Information

    First Posted
    December 19, 2008
    Last Updated
    April 7, 2017
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00813995
    Brief Title
    A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
    Official Title
    A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    December 9, 2008 (Actual)
    Primary Completion Date
    August 9, 2010 (Actual)
    Study Completion Date
    August 9, 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    395 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sitagliptin
    Arm Type
    Experimental
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Sitagliptin phosphate
    Other Intervention Name(s)
    GLUCOPHAGE®
    Intervention Description
    All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Placebo
    Other Intervention Name(s)
    GLUCOPHAGE®
    Intervention Description
    All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
    Primary Outcome Measure Information:
    Title
    Change From Baseline in Hemoglobin A1c (A1C) at Week 24
    Description
    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
    Time Frame
    Baseline and Week 24
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day
    Description
    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
    Time Frame
    Baseline and Week 24
    Title
    Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day
    Description
    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
    Time Frame
    Baseline and Week 24
    Title
    Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
    Description
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.
    Time Frame
    Baseline and Week 24
    Title
    Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
    Description
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.
    Time Frame
    Baseline and Week 24

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    78 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 18 - 78 years of age Currently on metformin monotherapy Exclusion Criteria: History of Type 1 diabetes mellitus or ketoacidosis Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery Currently participating in a study or has participated in a study with or without an investigational compound or device within the past 12 weeks History of active liver disease such as chronic active hepatitis B or C, cirrhosis or symptomatic gallbladder disease HIV positive Pregnant, breast-feeding or planning to become pregnant during the study User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
    Citations:
    PubMed Identifier
    22672586
    Citation
    Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012 Sep;4(3):227-37. doi: 10.1111/j.1753-0407.2012.00213.x.
    Results Reference
    derived

    Learn more about this trial

    A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

    We'll reach out to this number within 24 hrs